![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Diamedica Therapeutics | TSXV:DMA | TSX Venture | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.63 | 4.57 | 5.00 | 0 | 01:00:00 |
For 2018, DiaMedica is well positioned to make significant progress in the clinical development of DM199. Phase 2 clinical development is a critical stage for our Company and, along with our work to-date, we have significantly “de-risked” our development approach to treat stroke and kidney patients by restoring KLK1 levels. Early in 2018 we anticipate commencing patient enrollment in our Phase 2 clinical study for acute ischemic stroke, the REMEDY trial. Once we complete our upcoming meeting with the U.S. FDA, we plan to also initiate a Phase 2 clinical study of CKD in Type 1 diabetic patients. Our studies have been designed based on the extensive use of the crude (porcine and human urine) forms of the KLK1 protein as currently approved and used in Asia. We also intend to validate a companion diagnostic test which we have developed to evaluate patient’s KLK1 levels and potential suitability for treatment with DM199. In addition, we also plan to publish addition clinical and white papers to share our science and DM199’s clinical results with the investment and scientific community and anticipate additional important corporate developments.
As we look to 2018, we remain, as always, focused on the complete patient – the whole person – and our mission to help people lead fuller, richer, more productive lives by restoring KLK1 levels. This is a responsibility we take very seriously and continues to drive our work.
Once again, we wish to thank all of our shareholders for their support in 2017 and delighted to have you with us on what should be an exciting 2018!
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica’s shares are listed on the TSX Venture Exchange under the trading symbol “DMA” and on the OTCQB under the trading symbol “DMCAF”. For more information, please visit www.diamedica.com. Follow us on social media – Twitter, LinkedIn.
For further information, please contact:
Paul Papi Vice President of Business Development DiaMedica Therapeutics Inc. Two Carlson Parkway, Suite 260 Minneapolis, MN Phone: (617) 899-5941 info@diamedica.com
Tweet this!
FORWARD-LOOKING STATEMENTS
The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words “may”, “will”, “anticipate”, “believe”, “estimate”, “expect”, “intend” and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the DiaMedica’s filings with the Canadian securities regulators, all of which are available on SEDAR (www.sedar.com). Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
1 Year DiaMedica Inc. Chart |
1 Month DiaMedica Inc. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions